Cardio Diagnostics Holdings has received a contract from healthcare performance improvement company Vizient for access to AI-driven heart disease tests.
Under the contract, Vizient’s customer base, which includes a significant portion of hospitals and academic medical centres in the US, will have access to AI-driven precision heart disease tests.
With this contract, Cardio Diagnostics said it aims to make advanced cardiovascular care more accessible across the US.
The new agreement is effective from 1 November 2023 and covers Cardio Diagnostics’ AI-driven molecular heart disease tests, including the Epi+Gen CHD and PrecisionCHD tests.
The tests use AI to analyse epigenetic and genetic biomarkers from a patient’s blood sample, to identify individuals at risk of coronary heart disease.
The contract was awarded based on a recommendation from Vizient’s council of hospital experts, signifying the potential for improvement in the healthcare industry.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
Your download email will arrive shortly
We are confident about the
quality of our Company Profiles. However, we want you to make the most
decision for your business, so we offer a free sample that you can download by
submitting the below form
Cardio Diagnostics CEO Meesha Dogan said: “We are honoured to receive this contract from Vizient, which will accelerate access to our novel heart disease tests that leverage AI and a precision medicine approach.”
The contract covered products from several categories including biliary access (long wire and short wire), biopsy, cytology and polypectomy, extraction, dilation, drainage stenting, biliary/pancreatic therapy, stricture management and tissue management.
Last month, Cardio Diagnostics announced the launch of a new integrated research facility in Iowa City, Iowa. The facility will house the company’s new research laboratory and fulfilment centre. Initial operations are expected to commence in Q4 2023, with full operations set to begin in Q1 2024.